Thursday, September 23, 2021 12:24:56 PM
Basis for taking an AVXL position.
Interestingly, there are a number of divergent, otherwise unconnected reasons, I see, that equity buyers have or might decide to take an AVXL position.
1. The Investment Advisor Recommendation. In this case, a recommendation in some investor newsletter, blog, or webpage prompts an AVXL buy. The particular reasons the newsletter or investment advisor states are not as important as the recommendation itself. It comes from “someone who knows,” or has “a good record.” Good enough. “I’ll buy some of those.”
2. The FOMO (fear of missing out) Buy. In whatever way, an equity buyer discovers that, at least for the nonce, the AVXL share price is on a steep ascent. The person wants to catch that rise, so “buys low, to sell higher.” Few or no other data or information come into play.
3. The Day-Trading Play. It is noted that the AVXL share price tends, at times, to sharply ascend, then more slowly drop back to some “base price,” Day traders, expert in spotting and playing these moves, go in an out of AVXL positions, making a few percentage points of gains with each buy/sell trade pair.
4. The Technical Analysis (TA) Play. Those confident in TA see and act on various TA buy or sell signals. Trades are based solely on the AVXL or market TA charts and metrics; nothing else.
5. The Anavex Science and Potential Markets Play. AVXL positions taken with these criteria take into consideration the accuracy, validity, and potential applications of the existing, known ANAVEX science, as revealed in scholarly papers, informed postings, research, and corporate and institutional announcements; while also considering the potential markets for the ANAVEX drugs, once they might gain regulatory approval for sales and therapeutic uses.
Each of these will prompt varying time frames in which AVXL positions might be retained.
In Number 1, Investment Advisor Recommendation, positions may be held for some time, contingent on when the recommendations are to play out. Those are likely months or years.
In Number 2, the FOMO Buys, rather short term, for most. When the price ascent levels, time to take the gain and find another equity moving up rapidly. Of course, for some, the AVXL position is then retained for longer-term gains.
Number 3, Day-Traders, are in and out, often within minutes or hours. Nothing long-term here.
Number 4, TA Analysis plays, are probably a bit longer than day-trading. The charts decide.
Number 5, the Anavex Science and Markets plays, are decidedly long-term. Buy, and hold. Wait. Payoffs somewhere in the future; but particularly rewarding when they eventually happen.
Personally, my few thousand shares of AVXL have been purchased, and are retained, because of Number 5, the science and potential markets of Anavex Life Sciences Corp. I utterly reject all of the others, find nothing useful about them at all. But, I dully respect the many individuals who post messages on each of these. I read, and consider them all (but don’t act on any except the science postings). All good people, here; making this one of the most informative iHub message boards.
Interestingly, there are a number of divergent, otherwise unconnected reasons, I see, that equity buyers have or might decide to take an AVXL position.
1. The Investment Advisor Recommendation. In this case, a recommendation in some investor newsletter, blog, or webpage prompts an AVXL buy. The particular reasons the newsletter or investment advisor states are not as important as the recommendation itself. It comes from “someone who knows,” or has “a good record.” Good enough. “I’ll buy some of those.”
2. The FOMO (fear of missing out) Buy. In whatever way, an equity buyer discovers that, at least for the nonce, the AVXL share price is on a steep ascent. The person wants to catch that rise, so “buys low, to sell higher.” Few or no other data or information come into play.
3. The Day-Trading Play. It is noted that the AVXL share price tends, at times, to sharply ascend, then more slowly drop back to some “base price,” Day traders, expert in spotting and playing these moves, go in an out of AVXL positions, making a few percentage points of gains with each buy/sell trade pair.
4. The Technical Analysis (TA) Play. Those confident in TA see and act on various TA buy or sell signals. Trades are based solely on the AVXL or market TA charts and metrics; nothing else.
5. The Anavex Science and Potential Markets Play. AVXL positions taken with these criteria take into consideration the accuracy, validity, and potential applications of the existing, known ANAVEX science, as revealed in scholarly papers, informed postings, research, and corporate and institutional announcements; while also considering the potential markets for the ANAVEX drugs, once they might gain regulatory approval for sales and therapeutic uses.
Each of these will prompt varying time frames in which AVXL positions might be retained.
In Number 1, Investment Advisor Recommendation, positions may be held for some time, contingent on when the recommendations are to play out. Those are likely months or years.
In Number 2, the FOMO Buys, rather short term, for most. When the price ascent levels, time to take the gain and find another equity moving up rapidly. Of course, for some, the AVXL position is then retained for longer-term gains.
Number 3, Day-Traders, are in and out, often within minutes or hours. Nothing long-term here.
Number 4, TA Analysis plays, are probably a bit longer than day-trading. The charts decide.
Number 5, the Anavex Science and Markets plays, are decidedly long-term. Buy, and hold. Wait. Payoffs somewhere in the future; but particularly rewarding when they eventually happen.
Personally, my few thousand shares of AVXL have been purchased, and are retained, because of Number 5, the science and potential markets of Anavex Life Sciences Corp. I utterly reject all of the others, find nothing useful about them at all. But, I dully respect the many individuals who post messages on each of these. I read, and consider them all (but don’t act on any except the science postings). All good people, here; making this one of the most informative iHub message boards.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
